Literature DB >> 11806486

Effects of atypical antipsychotics on weight and serum lipid levels.

J M Meyer1.   

Abstract

Psychiatrists have become particularly concerned about health issues in patients with schizophrenia because of emerging data that link some of the newer atypical antipsychotics with both significant weight gain and increases in serum triglyceride levels. Excessive weight gain during antipsychotic therapy has an adverse effect on health and medication compliance, while hyperlipidemia presents an additional cardiovascular risk factor in patients with schizophrenia who typically smoke, are inactive, and possess poor dietary habits. An understanding of appropriate monitoring for metabolic adverse effects is important for those who prescribe atypical antipsychotics, as is a working knowledge of behavioral and pharmacologic treatments for weight gain and hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11806486

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

Review 1.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

3.  Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes.

Authors:  Emilie Lauressergues; Bart Staels; Karine Valeille; Zouher Majd; Dean W Hum; Patrick Duriez; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-24       Impact factor: 3.000

Review 4.  Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.

Authors:  Louis S Matza; Timothy M Baker; Dennis A Revicki
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.

Authors:  Steven M Grauer; Radka Graf; Rachel Navarra; Amy Sung; Sheree F Logue; Gary Stack; Christine Huselton; Zhi Liu; Thomas A Comery; Karen L Marquis; Sharon Rosenzweig-Lipson
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

Review 6.  Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.

Authors:  Hu Yan; Jin-Dong Chen; Xiao-Yan Zheng
Journal:  Psychopharmacology (Berl)       Date:  2013-07-06       Impact factor: 4.530

7.  Change in framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine.

Authors:  Megan C Del Valle; Antony D Loebel; Stephen Murray; Ruoyong Yang; David J Harrison; Brian J Cuffel
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

8.  A model for antipsychotic-induced obesity in the male rat.

Authors:  Julie Minet-Ringuet; Patrick C Even; Magali Lacroix; Daniel Tomé; Renaud de Beaurepaire
Journal:  Psychopharmacology (Berl)       Date:  2006-06-17       Impact factor: 4.530

Review 9.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

10.  The contribution of abdominal obesity and dyslipidemia to metabolic syndrome in psychiatric patients.

Authors:  Sung-Hwan Kim; Kiwon Kim; Mi Hyang Kwak; Hak Jin Kim; Hong-Sup Kim; Ki Hoon Han
Journal:  Korean J Intern Med       Date:  2010-06-01       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.